Suzhou and Boston-based Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” to emerge stronger post-pandemic, says the company founder, chairman and CEO Jinsong Wang in an extensive interview.